On July 22, Insilico Medicine rose 5.47% in regular trading, trading at 46.8 HKD/share, with turnover of approximately HKD 131 million.

On the news front, the Life Sciences Tools & Services sector strengthened broadly, with Pharmaron up 5.25%, JOINN up 4.19%, WuXi AppTec up 2.59%, and WuXi Bio up 1.96%. Additionally, the World Artificial Intelligence Conference continued to serve as a catalyst. The company recently participated as a strategic investor in YuanMa ZhiYao's Pre-A round financing worth tens of millions of yuan, and established a three-party collaboration with Shaqiu Quantum to enter the in-vivo CAR-T and mRNA drug development space.

The stock has seen significant momentum in recent weeks following a series of major deals, including a strategic alliance with Bora Pharmaceuticals potentially valued at over USD 2.5 billion, a collaboration with Takeda worth up to USD 600 million, and a mid-year profit alert forecasting net profit of USD 33.5-39.5 million versus a loss in the prior year period.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)